TICKERNOMICS Sign up
Last Update: 2023-12-23 06:02:47
C4 Therapeutics Inc. ( CCCC ) https://www.c4therapeutics.com
4.45USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
-26.81%
CCCC
SPY
30.72%
-87.99%
CCCC
SPY
112.82%
CCCC
0.00%
SPY
201.04%
CCCC
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
225.88
142.47
7.53
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-1.70
11.10
1.05
-57.98
0.00
-1.06
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-251.16
100.00
-661.99
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
3.86
-68.15
-30.75
0.00
Other Earnings and Cash Flow Stats:
C4 Therapeutics Inc. ( CCCC ) Net Income TTM ($MM) is -128.48
C4 Therapeutics Inc. ( CCCC ) Operating Income TTM ($MM) is -134.82
C4 Therapeutics Inc. ( CCCC ) Owners' Earnings Annual ($MM) is 0.00
C4 Therapeutics Inc. ( CCCC ) Current Price to Owners' Earnings ratio is 0.00
C4 Therapeutics Inc. ( CCCC ) EBITDA TTM ($MM) is -128.59
C4 Therapeutics Inc. ( CCCC ) EBITDA Margin is -661.99%
Capital Allocation:
C4 Therapeutics Inc. ( CCCC ) has paid 0.00 dividends per share and bought back -0.290198 million shares in the past 12 months
C4 Therapeutics Inc. ( CCCC ) has reduced its debt by 22.7 million USD in the last 12 months
Capital Structure:
C4 Therapeutics Inc. ( CCCC ) Interest-bearing Debt ($MM) as of last quarter is 72
C4 Therapeutics Inc. ( CCCC ) Annual Working Capital Investments ($MM) are -11
C4 Therapeutics Inc. ( CCCC ) Book Value ($MM) as of last quarter is 216
C4 Therapeutics Inc. ( CCCC ) Debt/Capital as of last quarter is 33%
Other Balance Sheet Stats:
C4 Therapeutics Inc. ( CCCC ) has 60 million in cash on hand as of last quarter
C4 Therapeutics Inc. ( CCCC ) has 30 million of liabilities due within 12 months, and long term debt 18 as of last quarter
C4 Therapeutics Inc. ( CCCC ) has 49 common shares outstanding as of last quarter
C4 Therapeutics Inc. ( CCCC ) has 0 million USD of preferred stock value
Academic Scores:
C4 Therapeutics Inc. ( CCCC ) Altman Z-Score is -1.54 as of last quarter
C4 Therapeutics Inc. ( CCCC ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
C4 Therapeutics Inc. ( CCCC ) largest shareholder is AQR Capital Management LLC owning 1093099 shares at 4.86 ($MM) value
Utpal Koppikar(an insider) Bought 5667 shares of C4 Therapeutics Inc. ( CCCC ) for the amount of $31735.20 on 2023-02-08
7.80% of C4 Therapeutics Inc. ( CCCC ) is held by insiders, and 66.84% is held by institutions
C4 Therapeutics Inc. ( CCCC ) went public on 2020-10-02
Other C4 Therapeutics Inc. ( CCCC ) financial metrics:
FCF:-126.96
Unlevered Free Cash Flow:0.00
EPS:-2.20
Operating Margin:-251.16
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-50.06
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About C4 Therapeutics Inc. ( CCCC ) :
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.